Georgia Bio Names Ashley Williams Haltom New VP of Government Affairs

Ashley Williams Haltom headshot

Atlanta, Georgia (December 11, 2020) – Georgia Bio, the state’s public policy and business solutions organization representing Georgia’s life sciences sector, announced an addition to its team hiring Ashley Williams Haltom as the Vice President of Government Affairs. In this role, she will provide expanded leadership in developing and implementing sound public policy strategies for Georgia Bio members and strengthen the voice of life sciences in the state.

“At this critical juncture, life sciences play a more prominent role than at any point in recent history. My top priority is to provide information and resources to policymakers on Georgia’s life sciences ecosystem and the important role that it plays in our state,” said Mrs. Haltom.

As Georgia’s biotechnology, medical device, agbio, and digital health communities continue to grow, the addition of Mrs. Haltom bolsters the organization’s government relations activities. Those activities seek to drive solution-oriented public policies and advocacy that support life sciences research, investment and innovation in the state.

Mrs. Haltom has almost a decade of experience working in politics and government, serving in roles with then-Governor Deal’s Office of Workforce Development, the Georgia House of Representatives, and state and federal campaigns. Most recently, she served as the Communications Director and Staff Lobbyist for a statewide trade association. She is a graduate of the University of Georgia with a degree in International Affairs.

“This role, with ongoing support from our lobbyist Cornerstone Government Affairs, will deepen our relationship with policymakers,” said Maria Thacker Goethe, Georgia Bio’s president and CEO. “Ashley will enhance awareness at the state level for the contributions our life sciences sector and member companies make to Georgia’s economy and improvements in patient care. I am delighted to welcome her to Georgia Bio.”

About Georgia Bio

Georgia Bio ( www.gabio.org ) is the state’s private, non-profit life sciences association. Members include pharmaceutical, biotechnology and medical device companies, medical centers, universities and research institutes, government groups and other business organizations involved in the development of life sciences related products and services.

Media Contact:
Kristina Forbes
404-920-2043
kforbes@gabio.org

By Maria Thacker Goethe October 22, 2025
“Evolving FTC and DOJ policies leave investors and innovators navigating a cautious M&A landscape
October 6, 2025
Atlanta, GA — October 6 — Georgia Life Sciences today announced the launch of Vitals, a new podcast series developed in partnership with Cloudcast Media, a leader in branded podcast production. The series will spotlight the people, ideas, and innovations shaping the future of Georgia’s rapidly growing life sciences sector. Hosted by Georgia Life Sciences’ CEO, Maria Thacker Goethe, Vitals will feature in-depth conversations with scientists, entrepreneurs, investors, educators, policymakers, and patient advocates. Each episode will explore the challenges and opportunities facing Georgia’s life sciences ecosystem—spanning biopharma, medical technology, digital health, and advanced manufacturing. “Vitals gives us a powerful platform to showcase the remarkable work happening within our state,” said Maria Thacker Goethe. “By sharing these stories, we’re highlighting not only groundbreaking science but also the collaboration and talent that make Georgia such a vibrant hub for health innovation.” Cloudcast Media, known for its expertise in storytelling and high-quality podcast production, will bring industry insights and technical support to ensure the series reaches audiences across Georgia and beyond. “We’re proud to partner with Georgia Life Sciences on Vitals,” said Charles Parisi, Founder and CEO of Cloudcast. “This series will elevate the voices of innovators who are advancing science, improving patient outcomes, and building Georgia’s reputation as a global life sciences leader. We are very excited that Cloudcast Atlanta can play a role in supporting Maria and the impactful work of Georgia Life Sciences.” The first episode of Vitals launched today and is available on Apple Podcasts, Spotify, and other major streaming platforms, as well as through the Georgia Life Sciences website.
October 1, 2025
September 30, 2025 WASHINGTON, D.C. – John F. Crowley, President and CEO of the Biotechnology Innovation Organization (BIO) released the following statement on Most Favored Nation policies: "For too many years, Americans have subsidized the research and development necessary to bring newer and better medicines to patients around the world. As we saw with defense spending and NATO, the solution is not to weaken a strategically important American industry, but for other countries to pay their fair share. “Today’s announcement in the Oval Office highlights the problems with a drug delivery system where half of the cost of innovative medicines goes to middlemen and distributors, and where the supply chain distorts prices paid by the American people. We support a new framework that addresses the cost of medicines by simplifying the system - and making medicines directly available to patients. “But importing socialist price controls through most-favored nation policies fundamentally does not address the imbalance in international pricing for innovative medicines. MFN will not lower the out-of-pocket prices that most Americans pay for medicines. Even worse, it will jeopardize the entrepreneurial spirit and deter the capital necessary for a vibrant and essential American biotechnology industry to thrive and may cause most harm to small and midsize biotech companies, which are responsible for discovering more than half of all new treatments. “Without these biotech innovators and a free-market system, we risk slower scientific progress, decreased access to new medicines, compromised national security, fewer American jobs and perhaps most tragically, a diminished hope for those suffering with illness and disease. There are much better ways to address this problem than MFN.” ###
MORE POSTS